SEC Form 4 · accession 0002050167-26-000023
Maze Therapeutics, Inc. · MAZE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Atul Dandekar
Officer — CSBO
Period of report
Aug 28, 2026
Accepted (ET)
Aug 31, 2026 · 6:32 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001842295
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 28, 2026 | M | 7,500 | $10.42 | A | 33,750 | D | |
| Common StockF2 | Aug 28, 2026 | S | 7,500 | $27.5765 | D | 26,250 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $10.42 | Aug 28, 2026 | M | 7,500 | D | — | Apr 11, 2031 | Common Stock | 7,500 | 14,143 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $28.01 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.